Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
23.49
+0.15 (0.64%)
Apr 24, 2025, 12:40 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
$610,029
Profits / Employee
$83,479
Market Cap
43.42B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 3,116 |
| Northwest Biotherapeutics | 25 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 374 |
| CytoDyn | 9 |
| American Oncology Network | 1,914 |
| Longduoduo Company | 49 |
Daiichi Sankyo Company News
- 3 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 12 days ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha
- 16 days ago - Daiichi Sankyo and AstraZeneca get EU approval for Datroway - Seeking Alpha
- 19 days ago - European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - Benzinga
- 24 days ago - DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer - Benzinga
- 4 weeks ago - Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed - Benzinga
- 6 weeks ago - Nosis Biosciences Announces Research Collaboration and Option Agreement with Daiichi Sankyo to Develop Cell-Targeted RNA Medicines - Business Wire
- 7 weeks ago - Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment - Seeking Alpha